Get started
Author

Varunika Savla

Observed name: Savla, Varunika
ORCID: 0009-0002-0281-5628
Observed ORCID: 0009-0002-0281-5628
OpenAlex ID: A5092083437
Presence of Tertiary Lymphoid Structures and Exhausted Tissue-Resident T Cells Determines Clinical Response to PD-1 Blockade in Renal Cell Carcinoma
2025 · Miya B. Hugaboom, Lena V. Wirth, et al. · Cancer Discovery · 50
PD-1 Expression on Intratumoral Regulatory T Cells Is Associated with Lack of Benefit from Anti–PD-1 Therapy in Metastatic Clear-Cell Renal Cell Carcinoma Patients
2023 · Thomas Denize, Opeyemi A. Jegede, et al. · Clinical Cancer Research · 36
PDF
Targeting G1–S-checkpoint-compromised cancers with cyclin A/B RxL inhibitors
2025 · Shilpa Singh, Catherine E. Gleason, et al. · Nature · 21
Biomarkers of response to first-line nivolumab therapy in patients with advanced renal cell carcinoma (RCC) enrolled in the HCRN GU16-260 trial.
2023 · Nourhan El Ahmar, Sayed Matar, et al. · Journal of Clinical Oncology · 4
PDF
Cyclin A/B RxL Macrocyclic Inhibitors to Treat Cancers with High E2F Activity
2024 · Shilpa Singh, Catherine E. Gleason, et al. · bioRxiv (Cold Spring Harbor Laboratory) · 3
Expression of the receptor tyrosine kinase AXL and clinical outcomes to cabozantinib and everolimus in patients with metastatic renal cell carcinoma enrolled in the METEOR trial.
2024 · Yasmin Nabil Laimon, Morgan Paul, et al. · Journal of Clinical Oncology · 3
PDF
Dissecting the Tumor Microenvironment to Identify Biomarkers of Outcome to Anti–PD-1 Therapy in Clear-Cell Renal Cell Carcinoma: Analyses of the HCRN GU16-260 Trial
2026 · Nourhan El Ahmar, Morgan A. Paul, et al. · Clinical Cancer Research · 2
PDF
EED Maintains the Small Cell Lung Cancer Neuroendocrine Phenotype and Drives Lung Cancer Histological Transformation
2025 · Yixiang Li, Yasmin N. Laimon, et al. · bioRxiv (Cold Spring Harbor Laboratory) · 2
38Presence of tertiary lymphoid structures and exhausted tissue-resident T cells determines clinical response to PD-1 blockade in renal cell carcinoma
2025 · Lena Wirth, Miya Hugaboom, et al. · The Oncologist · 1
PDF
Data from Presence of Tertiary Lymphoid Structures and Exhausted Tissue-Resident T Cells Determines Clinical Response to PD-1 Blockade in Renal Cell Carcinoma
2025 · Miya B. Hugaboom, Lena V. Wirth, et al. · 1
Tumor-infiltrating CD163-positive macrophages and clinical outcomes to first-line nivolumab therapy in patients with advanced clear cell renal cell carcinoma (ccRCC) enrolled in the HCRN GU16-260 trial.
2024 · Nourhan El Ahmar, Sayed Matar, et al. · Journal of Clinical Oncology · 1
Polycomb scaffolding subunit EED supports the SCLC neuroendocrine identity and EGFR-mutant LUAD-to-SCLC transformation
2026 · Yixiang Li, Yasmin N. Laimon, et al. · Journal of Clinical Investigation
Supplementary Table S9 from Dissecting the Tumor Microenvironment to Identify Biomarkers of Outcome to Anti–PD-1 Therapy in Clear-Cell Renal Cell Carcinoma: Analyses of the HCRN GU16-260 Trial
2026 · Nourhan El Ahmar, Morgan A. Paul, et al.
Supplementary Table S3 from Dissecting the Tumor Microenvironment to Identify Biomarkers of Outcome to Anti–PD-1 Therapy in Clear-Cell Renal Cell Carcinoma: Analyses of the HCRN GU16-260 Trial
2026 · Nourhan El Ahmar, Morgan A. Paul, et al.
Supplementary Table S6 from Dissecting the Tumor Microenvironment to Identify Biomarkers of Outcome to Anti–PD-1 Therapy in Clear-Cell Renal Cell Carcinoma: Analyses of the HCRN GU16-260 Trial
2026 · Nourhan El Ahmar, Morgan A. Paul, et al.
Supplementary Table S4 from Dissecting the Tumor Microenvironment to Identify Biomarkers of Outcome to Anti–PD-1 Therapy in Clear-Cell Renal Cell Carcinoma: Analyses of the HCRN GU16-260 Trial
2026 · Nourhan El Ahmar, Morgan A. Paul, et al.
Supplementary Table S7 from Dissecting the Tumor Microenvironment to Identify Biomarkers of Outcome to Anti–PD-1 Therapy in Clear-Cell Renal Cell Carcinoma: Analyses of the HCRN GU16-260 Trial
2026 · Nourhan El Ahmar, Morgan A. Paul, et al.
Supplementary Table S11 from Dissecting the Tumor Microenvironment to Identify Biomarkers of Outcome to Anti–PD-1 Therapy in Clear-Cell Renal Cell Carcinoma: Analyses of the HCRN GU16-260 Trial
2026 · Nourhan El Ahmar, Morgan A. Paul, et al.
Supplementary Table S10 from Dissecting the Tumor Microenvironment to Identify Biomarkers of Outcome to Anti–PD-1 Therapy in Clear-Cell Renal Cell Carcinoma: Analyses of the HCRN GU16-260 Trial
2026 · Nourhan El Ahmar, Morgan A. Paul, et al.
Supplementary Figure S1 from Dissecting the Tumor Microenvironment to Identify Biomarkers of Outcome to Anti–PD-1 Therapy in Clear-Cell Renal Cell Carcinoma: Analyses of the HCRN GU16-260 Trial
2026 · Nourhan El Ahmar, Morgan A. Paul, et al.
Data from Dissecting the Tumor Microenvironment to Identify Biomarkers of Outcome to Anti–PD-1 Therapy in Clear-Cell Renal Cell Carcinoma: Analyses of the HCRN GU16-260 Trial
2026 · Nourhan El Ahmar, Morgan A. Paul, et al.
Supplementary Table S8 from Dissecting the Tumor Microenvironment to Identify Biomarkers of Outcome to Anti–PD-1 Therapy in Clear-Cell Renal Cell Carcinoma: Analyses of the HCRN GU16-260 Trial
2026 · Nourhan El Ahmar, Morgan A. Paul, et al.
Supplementary Table S5 from Dissecting the Tumor Microenvironment to Identify Biomarkers of Outcome to Anti–PD-1 Therapy in Clear-Cell Renal Cell Carcinoma: Analyses of the HCRN GU16-260 Trial
2026 · Nourhan El Ahmar, Morgan A. Paul, et al.
Supplementary Figure S5 from Dissecting the Tumor Microenvironment to Identify Biomarkers of Outcome to Anti–PD-1 Therapy in Clear-Cell Renal Cell Carcinoma: Analyses of the HCRN GU16-260 Trial
2026 · Nourhan El Ahmar, Morgan A. Paul, et al.
Supplementary Figure S2 from Dissecting the Tumor Microenvironment to Identify Biomarkers of Outcome to Anti–PD-1 Therapy in Clear-Cell Renal Cell Carcinoma: Analyses of the HCRN GU16-260 Trial
2026 · Nourhan El Ahmar, Morgan A. Paul, et al.
Works count: 113
Citation count: 124
H-index: 4
I10-index: 3
Year
Topic
Type